menu

On the Forefront of NSCLC Treatment: Targeting RET Mutations

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

On the Forefront of NSCLC Treatment: Targeting RET Mutations

close
On the Forefront of NSCLC Treatment: Targeting RET Mutations
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/24/20